Table 2. Point estimates for post-discharge long-term neurological sequelae among severe (vs. non-severe) COVID-19 patients.

aOR: adjusted odds ratio; CI: confidence interval

Study	Study design	Sample size (n=651)	Anosmia	Fatigue	Headache	Dysgeusia	Myalgia
Jacobs et al., USA, Dec 2020 [7]	Prospective cohort study	183	aOR: 1.96; 95% CI: 0.99-3.89	aOR: 0.93; 95% CI: 0.60-1.44	aOR: 4.23; 95% CI: 2.15-8.33	aOR: 1.05; 95% CI: 0.56-1.98	aOR: 4.05; 95% CI: 2.28-7.19
Fisher et al., USA, Jan 2021 [8]	Matched case-control study	320	aOR: 32.40; 95% CI: 2.60‐83.32	aOR: 3.30; 95% CI: 2.60‐4.19	Not estimated	aOR: 32.40; 95% CI: 12.60‐83.32	aOR: 3.30; 95% CI: 2.60‐4.19
Walsh-Messinger et al., USA, Nov 2020 [9]	Preliminary report, online study	148	aOR: 4.09; 95% CI: 1.03-16.28	aOR: 10.45; 95% CI: 1.93-56.64	aOR: 9.33; 95% CI: 1.03-84.21	aOR: 2.33; 95% CI: 0.69-7.95	aOR: 2.33; 95% CI: 0.69-7.95